Paradoxical Rebound Platelet Activation After Painkillers Cessation: Missing Risk for Vascular Events?

Victor L. Serebruany, Alex I. Malinin, Deepak L. Bhatt

Research output: Contribution to journalArticle

Abstract

Background: Several reliable reports strongly indicate that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors is associated with an increased risk of cardiovascular events. Considering the key role of platelets in coronary atherosclerosis and the fact that antiplatelet therapy with aspirin (and more recently, clopidogrel) has been associated with reduced vascular mortality, we sought to determine the effect of therapy and withdrawal of NSAIDs and COX-2 inhibitors on platelet activity. Methods: Platelet characteristics from 34 aspirin-naive volunteers who were receiving NSAIDs and COX-2 inhibitors were compared with 138 drug-free controls. Platelets were assessed twice at baseline (at least 1 month of NSAIDs and COX-2 inhibitors) and after a 14-day washout. We used adenosine diphosphate-induced conventional aggregometry, the point-of-care Ultegra analyzer (Ultegra Accumetrics, San Diego, Calif), and whole blood flow cytometry. Results: Platelet activity during therapy with NSAIDs and COX-2 inhibitors was similar and unremarkable between groups. However, there was a highly significant increase of platelet activity as assessed by conventional aggregometry (P = .0003), Ultegra analyzer readings (P = .03), and expression of GPIIb/IIIa (P = .02), P-selectin (P = .03), and platelet endothelial cell adhesion molecule-1 (P = .001) after withdrawal from NSAIDs and COX-2 inhibitors. Conclusions: These data suggest that drug cessation, rather than continuous therapy with NSAIDs and COX-2 inhibitors, may be associated with rebound platelet activation, which may predispose one to a higher risk of vascular events. This hypothesis requires intensive testing in crossover randomized studies and may justify more aggressive antiplatelet regimens in patients after discontinuation of therapy with NSAIDs and COX-2 inhibitors.

Original languageEnglish (US)
JournalAmerican Journal of Medicine
Volume119
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Platelet Activation
Cyclooxygenase 2 Inhibitors
Blood Vessels
Anti-Inflammatory Agents
Blood Platelets
Pharmaceutical Preparations
clopidogrel
Aspirin
Point-of-Care Systems
CD31 Antigens
Therapeutics
P-Selectin
Drug and Narcotic Control
Cross-Over Studies
Adenosine Diphosphate
Reading
Coronary Artery Disease
Volunteers
Flow Cytometry
Mortality

Keywords

  • Cardiovascular risk
  • COX-2 inhibitors
  • NSAIDs
  • Platelets

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Paradoxical Rebound Platelet Activation After Painkillers Cessation : Missing Risk for Vascular Events? / Serebruany, Victor L.; Malinin, Alex I.; Bhatt, Deepak L.

In: American Journal of Medicine, Vol. 119, No. 8, 08.2006.

Research output: Contribution to journalArticle

Serebruany, Victor L. ; Malinin, Alex I. ; Bhatt, Deepak L. / Paradoxical Rebound Platelet Activation After Painkillers Cessation : Missing Risk for Vascular Events?. In: American Journal of Medicine. 2006 ; Vol. 119, No. 8.
@article{61d605b95d4a4a57b342bf532ab8e3b3,
title = "Paradoxical Rebound Platelet Activation After Painkillers Cessation: Missing Risk for Vascular Events?",
abstract = "Background: Several reliable reports strongly indicate that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors is associated with an increased risk of cardiovascular events. Considering the key role of platelets in coronary atherosclerosis and the fact that antiplatelet therapy with aspirin (and more recently, clopidogrel) has been associated with reduced vascular mortality, we sought to determine the effect of therapy and withdrawal of NSAIDs and COX-2 inhibitors on platelet activity. Methods: Platelet characteristics from 34 aspirin-naive volunteers who were receiving NSAIDs and COX-2 inhibitors were compared with 138 drug-free controls. Platelets were assessed twice at baseline (at least 1 month of NSAIDs and COX-2 inhibitors) and after a 14-day washout. We used adenosine diphosphate-induced conventional aggregometry, the point-of-care Ultegra analyzer (Ultegra Accumetrics, San Diego, Calif), and whole blood flow cytometry. Results: Platelet activity during therapy with NSAIDs and COX-2 inhibitors was similar and unremarkable between groups. However, there was a highly significant increase of platelet activity as assessed by conventional aggregometry (P = .0003), Ultegra analyzer readings (P = .03), and expression of GPIIb/IIIa (P = .02), P-selectin (P = .03), and platelet endothelial cell adhesion molecule-1 (P = .001) after withdrawal from NSAIDs and COX-2 inhibitors. Conclusions: These data suggest that drug cessation, rather than continuous therapy with NSAIDs and COX-2 inhibitors, may be associated with rebound platelet activation, which may predispose one to a higher risk of vascular events. This hypothesis requires intensive testing in crossover randomized studies and may justify more aggressive antiplatelet regimens in patients after discontinuation of therapy with NSAIDs and COX-2 inhibitors.",
keywords = "Cardiovascular risk, COX-2 inhibitors, NSAIDs, Platelets",
author = "Serebruany, {Victor L.} and Malinin, {Alex I.} and Bhatt, {Deepak L.}",
year = "2006",
month = "8",
doi = "10.1016/j.amjmed.2005.11.007",
language = "English (US)",
volume = "119",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Paradoxical Rebound Platelet Activation After Painkillers Cessation

T2 - Missing Risk for Vascular Events?

AU - Serebruany, Victor L.

AU - Malinin, Alex I.

AU - Bhatt, Deepak L.

PY - 2006/8

Y1 - 2006/8

N2 - Background: Several reliable reports strongly indicate that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors is associated with an increased risk of cardiovascular events. Considering the key role of platelets in coronary atherosclerosis and the fact that antiplatelet therapy with aspirin (and more recently, clopidogrel) has been associated with reduced vascular mortality, we sought to determine the effect of therapy and withdrawal of NSAIDs and COX-2 inhibitors on platelet activity. Methods: Platelet characteristics from 34 aspirin-naive volunteers who were receiving NSAIDs and COX-2 inhibitors were compared with 138 drug-free controls. Platelets were assessed twice at baseline (at least 1 month of NSAIDs and COX-2 inhibitors) and after a 14-day washout. We used adenosine diphosphate-induced conventional aggregometry, the point-of-care Ultegra analyzer (Ultegra Accumetrics, San Diego, Calif), and whole blood flow cytometry. Results: Platelet activity during therapy with NSAIDs and COX-2 inhibitors was similar and unremarkable between groups. However, there was a highly significant increase of platelet activity as assessed by conventional aggregometry (P = .0003), Ultegra analyzer readings (P = .03), and expression of GPIIb/IIIa (P = .02), P-selectin (P = .03), and platelet endothelial cell adhesion molecule-1 (P = .001) after withdrawal from NSAIDs and COX-2 inhibitors. Conclusions: These data suggest that drug cessation, rather than continuous therapy with NSAIDs and COX-2 inhibitors, may be associated with rebound platelet activation, which may predispose one to a higher risk of vascular events. This hypothesis requires intensive testing in crossover randomized studies and may justify more aggressive antiplatelet regimens in patients after discontinuation of therapy with NSAIDs and COX-2 inhibitors.

AB - Background: Several reliable reports strongly indicate that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors is associated with an increased risk of cardiovascular events. Considering the key role of platelets in coronary atherosclerosis and the fact that antiplatelet therapy with aspirin (and more recently, clopidogrel) has been associated with reduced vascular mortality, we sought to determine the effect of therapy and withdrawal of NSAIDs and COX-2 inhibitors on platelet activity. Methods: Platelet characteristics from 34 aspirin-naive volunteers who were receiving NSAIDs and COX-2 inhibitors were compared with 138 drug-free controls. Platelets were assessed twice at baseline (at least 1 month of NSAIDs and COX-2 inhibitors) and after a 14-day washout. We used adenosine diphosphate-induced conventional aggregometry, the point-of-care Ultegra analyzer (Ultegra Accumetrics, San Diego, Calif), and whole blood flow cytometry. Results: Platelet activity during therapy with NSAIDs and COX-2 inhibitors was similar and unremarkable between groups. However, there was a highly significant increase of platelet activity as assessed by conventional aggregometry (P = .0003), Ultegra analyzer readings (P = .03), and expression of GPIIb/IIIa (P = .02), P-selectin (P = .03), and platelet endothelial cell adhesion molecule-1 (P = .001) after withdrawal from NSAIDs and COX-2 inhibitors. Conclusions: These data suggest that drug cessation, rather than continuous therapy with NSAIDs and COX-2 inhibitors, may be associated with rebound platelet activation, which may predispose one to a higher risk of vascular events. This hypothesis requires intensive testing in crossover randomized studies and may justify more aggressive antiplatelet regimens in patients after discontinuation of therapy with NSAIDs and COX-2 inhibitors.

KW - Cardiovascular risk

KW - COX-2 inhibitors

KW - NSAIDs

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=33746412348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746412348&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2005.11.007

DO - 10.1016/j.amjmed.2005.11.007

M3 - Article

C2 - 16887419

AN - SCOPUS:33746412348

VL - 119

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 8

ER -